Start here if you're new
what it is
Boston Scientific sells the tools doctors use in minimally invasive procedures, from heart devices to scopes for the lungs, gut, and urinary tract.
how it gets paid
Last year Boston Scientific made $20.1B in revenue. Cardiology was the main engine at $6.3B, or 31% of sales.
why it's growing
Revenue grew 19.9% last year. The hard numbers looked strong on paper, with revenue up 192% vs. prior year and gross margin at 68.8%.
what just happened
Boston Scientific posted $1.49 EPS on $14.8B of revenue, but the market was still focused on a prior guidance stumble and softer EP commentary.
At a glance
A balance sheet — strong enough to weather a downturn
75/100 earnings predictability — reasonably predictable
30.7x trailing p/e — you're paying up for this one
19.0% return on capital — nothing to write home about
xvary composite: 72/100 — average
What they do
Boston Scientific sells the tools doctors use in minimally invasive procedures, from heart devices to scopes for the lungs, gut, and urinary tract.
This business sits where you do not want experiments: inside the body, during a procedure, with a physician who already knows the tool. That makes switching costly (switching costs → changing vendors is a hassle and a risk → hospitals stick with what works). Boston Scientific spends 9.6% of sales on R&D and generates a 19.0% return on capital, which says those products are not commodity metal with a logo.
How they make money
$20.1B
annual revenue · their business grew +19.9% last year
Cardiology
$6.3B
+12.0%
Electrophysiology
$4.2B
+15.0%
Peripheral Interventions
$3.5B
+9.0%
Endoscopy
$2.8B
+8.0%
Urology
$1.9B
+10.0%
Neuromodulation
$1.4B
+7.0%
The products that matter
stroke-prevention implant
WATCHMAN
core cardiovascular exposure
WATCHMAN is one of the names investors actually know here, which is rare in medtech. The company cited slower market growth around this business in the 2026 guidance cut, so it matters far beyond product marketing.
guidance pressure point
heart rhythm systems
Electrophysiology systems
the segment that moved the stock
Weaker U.S. electrophysiology sales were the quiet part said loud in the sell-off. One softer category was enough to knock 17.6% off the share price in a day.
17.6% reaction
heart valve platform
TAVR valves
inside the $10.8B cardiovascular segment
TAVR sits inside the biggest revenue bucket on the page. You do not have product-level sales here, but you do know the segment grew 12%, which is enough to show where Boston Scientific still has scale.
scale business
Key numbers
$124
18-month target
The base case sits $30.45 above the current $93.55 price, or 33% upside. That is the market saying the recent drop may have overshot.
19.0%
return on capital
Return on capital → profit earned on the money put into the business → so what: BSX turns investment into real earnings better than most large companies.
30.7x
trailing p/e
P/E → how many dollars investors pay for $1 of profit → so what: you are paying up for quality, which leaves less room for mistakes.
18.0%
operating margin
Operating margin → what the company keeps after running the business → so what: this is a real earner, not a growth story held together by slides.
Financial health
A
strength
- balance sheet grade A — very strong financial position
- risk rank 2 — safer than 80% of stocks
- price stability 90 / 100
- long-term debt $11.1B (7% of capital)
- net profit margin 25.1% — keeps 25 cents of every dollar in revenue
- return on equity 24% — $0.24 profit for every $1 investors have put in
A with balance sheet grade and risk rank standing out. your money faces less risk here than at most public companies.
Total return vs. market
You invested $10,000 in BSX 3 years ago → it's now worth $20,180.
The index would have given you $14,770.
source: institutional data · total return
What just happened
missed estimates
Boston Scientific posted $1.49 EPS on $14.8B of revenue, but the market was still focused on a prior guidance stumble and softer EP commentary.
The hard numbers looked strong on paper, with revenue up 192% vs. prior year and gross margin at 68.8%. The problem was trust: investors had already seen a 43.75% earnings miss versus expectations in the last reported comparison point.
$5.3B
revenue
$1.49
eps
68.8%
gross margin
the number that mattered
The number that mattered was the 43.75% miss versus estimates, because one miss can matter more to a 30.7x stock than one strong quarter.
-
boston scientific has entered an agreement to acquire penumbra, inc.under the terms of the deal, penumbra shareholders would receive $374 per share in cash for each share owned, in a deal valued at $14.5 billion.
-
if the merger happens, it would expand boston’s cardiovascular portfolio.
-
additional mergers are in the works.plans to acquire pain management company nalu medical for $533 million are ongoing, and scheduled to close by mid-2026.
-
there are also moves being made to purchase valencia technologies.valencia’s portfolio is centered around innovations intended to treat bladder dysfunction, and already has an fdaapproved system, e-coin, within this medical area.
-
the company is scheduled to release 2025 full-year results after this issue was published.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
Boston Scientific's risk is not "medical devices are hard." You already know that. The real risk is that a stock priced for steady execution just showed you what happens when one important category slows down.
med
Electrophysiology stays soft
Weaker U.S. electrophysiology sales were central to the 17.6% one-day drop and the lower 2026 outlook. If the next few quarters show the same pattern, the market stops treating this as a one-off miss.
Why it matters for you: a premium multiple usually compresses before the income statement fully shows the damage.
med
The lawsuit becomes a credibility problem
A securities class action alleges executives misled investors about electrophysiology growth between July 2025 and February 2026. You do not need a final court outcome for this to matter. A credibility overhang alone can weigh on sentiment.
Why it matters for you: when guidance is already under scrutiny, legal noise makes every future target harder to trust.
med
Valuation loses its premium
BSX trades at 30.7x trailing earnings while peers sit closer to 25x. That gap is manageable when growth is running clean. It is not forgiving when growth slips.
Why it matters for you: the stock does not need bad numbers to fall. It just needs numbers that look less special.
The key insight: operations, legal credibility, and valuation are all tied together right now. If one wobbles, the other two stop providing cover.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
Q1 2026 earnings report
Scheduled for April 29, 2026. Watch whether management keeps the 2026 adjusted EPS guide at $3.43–$3.49 or has to trim it again.
growth
Electrophysiology demand read-through
This is the category that moved the stock. If U.S. electrophysiology stabilizes, the sell-off starts to look overdone. If it does not, the market will keep cutting the multiple first and asking questions second.
legal
Class action case developments
The filing date listed here is March 2, 2026. You are watching for any motion, dismissal, or discovery headline that changes the credibility backdrop.
capital return
$5B buyback execution
The board authorized a $5B repurchase program on Feb 24, 2026. A fast repurchase pace would say management thinks the market overreacted. A slow pace would say cash has other priorities.
Analyst rankings
earnings predictability
75 / 100
in human-speak, analysts think management is usually dependable — but the latest guide reminds you this is predictability, not immunity
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 925 buyers vs. 668 sellers in 3q2025. total institutional holdings: 1.3B shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$82
$165
$94
current price
$124
target midpoint · +33% from current · 3-5yr high: $165 (+75% · 15% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive